Clinical Trials

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT07221474 2026-05-26

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07252739 2026-05-26

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT07353957 2026-05-26

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

180 enrolled

Lung Neoplasms

NCT01174121 2026-05-22

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

BreastGastrointestinalGynecologic

332 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06041503 2026-05-22

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

68 enrolled

Adenocarcinoma of the Bladder

NCT06770582 2026-05-22

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Lymphoid

Hodgkin Disease

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

182 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05355051 2026-05-18

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

24 enrolled

Lymphoid

Hodgkin Disease

NCT06083844 2026-05-18

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

46 enrolled

Endometrial Neoplasms

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

240 enrolled

Muscle-invasive Bladder Cancer

NCT07089992 2026-05-14

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

32 enrolled

Sarcoma

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

NCT04379596 2026-05-13

DG-03

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05239624 2026-05-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07098988 2026-05-13

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Other solid neoplasmThoracic

107 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT07172256 2026-05-13

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

Squamous Cell Carcinoma of Head and Neck

NCT05420948 2026-05-12

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04348747 2026-05-11

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

23 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT05903833 2026-05-11

PIERCE

42 enrolled

Vulvar Neoplasms

NCT02621021 2026-05-08

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

170 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT04671667 2026-05-08

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

188 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05155033 2026-05-08

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

DermatologicGenitourinary

78 enrolled

Carcinoma, Renal Cell, Melanoma

NCT07087860 2026-05-08

RECIPE-B1

70 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Uterine Cervical Neoplasms

NCT06845319 2026-05-06

NeoCARD

43 enrolled

Triple Negative Breast Neoplasms

NCT04317534 2026-05-05

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

244 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05956041 2026-05-05

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

23 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT07017829 2026-05-05

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05327686 2026-05-04

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT05358548 2026-04-30

ATATcH Alternating Treatment Plans for Advanced Cancer

150 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

DermatologicGastrointestinalHead & Neck

72 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT04332874 2026-04-23

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Sarcoma

Sarcoma, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Histiocytoma, Malignant Fibrous

NCT06157151 2026-04-23

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

24 enrolled

Uterine Cervical Neoplasms

NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Lymphoid

Hodgkin Disease

NCT05583708 2026-04-22

iPRRT

18 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

372 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

35 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05852223 2026-04-20

NePenThe

25 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT05197322 2026-04-17

NEOPRISM-CRC